Allarity Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $1.08 | $1.17 | $330.60 | $246,960.00 | $8,715,000.00 | |
| P/S | — | 53.4x | — | — | — | — |
| P/B | 1.7x | 1.7x | 1.7x | — | — | 5.3x |
| EPS | -$0.78 | -$15.65 | -$6,156.00 | -$1,856,052.00 | -$3,519,600.00 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ABVCABVC Biopharma Inc | $0.83 | — | 2.1x | — | -69.86% | $22.12M |
| MRKRMarker Therapeutics, Inc. | $1.37 | — | 1.9x | — | -76.87% | $22.84M |
| RVPRetractable Technologies Inc | $0.73 | — | 0.3x | — | -4.51% | $21.85M |
| CNSYCerenome Inc | $3.05 |
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
Company description provided by Yahoo Finance.
| Profit margin | — | -3509.69% | — | — | — | — |
| ROE | -146.80% | -114.28% | -207.56% | — | — | -146.80% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 1.1x |
| 4.1x |
| — |
| -614.05% |
| $23.15M |
| JSPRJasper Therapeutics, Inc. | $0.70 | — | 14.0x | — | -255.04% | $23.28M |
| BNGOBionano Genomics, Inc. | $1.82 | — | 0.7x | — | -83.56% | $21.43M |